Company Name
CHEMPRO PHARMA PRIVATE LIMITED
Year of Establishment
2006
Company Introduction
Chempro is a leading manufacturer and supplier of pharmaceuticals and developer of technologies for Key Starting Intermediates, APIs, Pellets, Finished Dosage Forms, OTC & Nutraceuticals, Impurities and Reference Standards. We are a globally renowned supply chain and sourcing partner to 50+ leading pharmaceutical companies across Asia, Europe, North, Central and South America, having 40+ years of experience. It is present in 40+ countries and offers a one-stop solution to Pharmaceutical customers worldwide. We are an ISO-compliant company having access to facilities with WHO-GMP, KFDA, PMDA, EU-GMP, and USFDA and committed to ensuring the profitable growth of its worldwide pharmaceutical partners.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Website
https://www.chemprogroup.com/pharma/index.html
Other Competitive Advantages
We offer a comprehensive range of biosimilar products designed to enhance access to vital treatments across various therapeutic areas. Our products adhere to the highest regulatory standards, ensuring both patient safety and therapeutic equivalence, and are available in ready-to-use form
Milestone
2001: Started production of APIs from advanced intermediates developed in-house.
2003: Obtained WHO-GMP for manufacturing facilities and began production of Finished Formulations.
2005: Established presence in Latin America.
2006: Began South East Asian operations in Thailand, Philippines, Hong Kong, Malaysia and Myanmar.
2008: Company turnover crossed USD 10 Million.
2009: Acquired new API Manufacturing Plant with purification technology.
2012: Started production at EU-GMP approved unit for solid dosage forms. Commenced registration of Finished Formulations in CIS countries and Latin America. Company's turnover crossed USD 25 million. Established presence in United Kingdom.
2014: Started a new division for Nutraceutical Products.
2016: Started a new division for Veterinary APIs and Formulations.
2017: Started 2 Units for Injectables, Ointments and Nasal Drops. Established Presence in Germany.
2021: Launched a new division for Natural and Plant Extracts, expanding our portfolio with sustainable, plant-based solutions.
2023: Initiated Tech Transfer and Turnkey Projects, enhancing our capabilities to deliver end-to-end solutions for global partners.
2025: Launched our comprehensive range of Biosimilar products, expanding access to essential treatments across multiple therapeutic areas.